B2M and colorectal carcinoma: The one patient with stage III disease in our study did not recur, nor did six other patients with stage III B2M‐mutant tumours in the only other prospective study.12 If patients with B2M‐mutant stage III dMMR CRC are also protected from recurrence, B2M mutation status would have additional clinical utility.